Joseph Klein III Sells 3,000 Shares of Ionis Pharmaceuticals Inc (IONS) Stock

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $51.69, for a total transaction of $155,070.00. Following the transaction, the director now directly owns 12,939 shares in the company, valued at $668,816.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Joseph Klein III also recently made the following trade(s):

  • On Saturday, December 29th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $50.56, for a total transaction of $151,680.00.
  • On Friday, December 29th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $50.56, for a total transaction of $151,680.00.
  • On Thursday, November 30th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $53.55, for a total transaction of $160,650.00.
  • On Wednesday, November 15th, Joseph Klein III sold 2,250 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $53.56, for a total transaction of $120,510.00.
  • On Monday, November 13th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $55.39, for a total transaction of $166,170.00.

Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) traded down $0.93 on Thursday, reaching $52.82. 171,462 shares of the company traded hands, compared to its average volume of 898,009. Ionis Pharmaceuticals Inc has a 1 year low of $37.26 and a 1 year high of $65.51. The stock has a market cap of $6,570.00, a P/E ratio of 377.29 and a beta of 2.86. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25.

A number of institutional investors and hedge funds have recently made changes to their positions in IONS. Vanguard Group Inc. increased its stake in Ionis Pharmaceuticals by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after buying an additional 417,364 shares during the period. American Century Companies Inc. grew its holdings in Ionis Pharmaceuticals by 33.0% during the 3rd quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock worth $58,027,000 after acquiring an additional 284,266 shares in the last quarter. First Trust Advisors LP grew its holdings in Ionis Pharmaceuticals by 40.2% during the 3rd quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock worth $49,805,000 after acquiring an additional 281,733 shares in the last quarter. BlackRock Inc. grew its holdings in Ionis Pharmaceuticals by 4.0% during the 2nd quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after acquiring an additional 264,179 shares in the last quarter. Finally, Aviva PLC acquired a new position in Ionis Pharmaceuticals during the 2nd quarter worth approximately $10,187,000. 91.40% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have recently issued reports on IONS shares. Goldman Sachs Group reissued a “sell” rating and issued a $30.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, October 6th. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price target on the stock in a research note on Friday, October 27th. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Sunday, September 17th. Stifel Nicolaus reissued a “hold” rating and issued a $50.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Finally, BidaskClub raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $50.76.

TRADEMARK VIOLATION NOTICE: “Joseph Klein III Sells 3,000 Shares of Ionis Pharmaceuticals Inc (IONS) Stock” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/11/ionis-pharmaceuticals-inc-ions-director-sells-155070-00-in-stock.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply